The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out a key provision that would have expanded coverage for weight-loss drugs. In response, Eli Lilly stock ...

What they don't tell you about Ozempic Weight-loss drugs like Ozempic and Wegovy have helped millions of Americans lose ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be covered by Medicare and Medicaid, expanding access for roughly 3.4 million ...

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

"Historically, anti-obesity drugs have been plagued by failures, often proving ineffective or unsustainable. However, a new class of medications known as GLP-1 receptor agonists has shown ...

Pharma giant Eli Lilly has launched a new anti-obesity and diabetes drug in India called Mounjaro. Image courtesy: Adobe Stock US pharma giant Eli Lilly has ventured into India with an anti-obesity ...

with people flocking to purchase medication like Ozempic in hopes of losing a few pounds. However, this can prove to be extremely harmful. Anti-obesity medication is often extremely powerful, and so ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Competition is intense as the two companies battle for dominance in a market that has grown tenfold since 2020 to see the global spend on anti-obesity medications top $30 billion in 2024 ...